Incidence of diabetes following ramipril or rosiglitazone withdrawal

Diabetes Care

Volumn 34, Issue 6, 2011, Pages 1265-1269

  Holman, Rury R ^a   Zinman, Bernie ^b   Yusuf, Salim ^c   Sheridan, Patrick M ^c   Anand, Sonia S ^c   Bosch, Jackie J ^d   Conget, Ignacio ^e   Davies, Melanie J ^f   Pirags, Valdis ^g   Dagenais, Gilles R ^h   Pogue, Janice M ⁱ   Zimmet, Paul Z ^j   Gerstein, Hertzel C ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MOUNT SINAI HOSPITAL   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e HOSPITAL CLÍNIC   (Spain)

^f UNIVERSITY OF LEICESTER   (United Kingdom)

^g UNIVERSITY OF LATVIA   (Latvia)

^h LAVAL UNIVERSITY   (Canada)

ⁱ HAMILTON GENERAL HOSPITAL   (Canada)

^j BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; PLACEBO; RAMIPRIL; ROSIGLITAZONE;

ARTICLE; DIABETES MELLITUS; DRUG DOSE TITRATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; MORTALITY; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; RAMIPRIL; SUBSTANCE WITHDRAWAL SYNDROME; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 80052005364     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-1567     Document Type: Article

References (9)

1. Gerstein H.C., Yusuf S., Holman R.R., Bosch J., Pogue J.; DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: The DREAM trial. Diabetologia 2004;47:1519-1527 (Pubitemid 39371633)
2. Gerstein H.C., Yusuf S., Bosch J., et al.; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 2006;368:1096-1105
3. Bosch J., Yusuf S., Gerstein H.C., et al.; DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-1562 (Pubitemid 44550032)
4. Buchanan T.A., Xiang A.H., Peters R.K., et al. Preservation of pancreatic b-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-2803 (Pubitemid 34970933)
5. Knowler W.C., Hamman R.F., Edelstein S.L., et al.; Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005;54:1150-1156 (Pubitemid 40446330)
6. Turner R.C., Cull C.A., Stratton I.M., et al. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type 2 diabetes: A progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995;44:1249-1258
7. Yudkin P.L., Stratton I.M. How to deal with regression to themean in intervention studies. Lancet 1996;347:241-243 (Pubitemid 26035252)
8. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M.; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002;359:2072-2077 (Pubitemid 34680970)
9. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003;26:977-980